Ind-Swift Q2 revenue rose 50% as EBITDA margin reached 18.02%

Ind-Swift Laboratories Limited reported Q2 FY27 operating revenue of Rs 234.89 crore, up 50.15% year on year, and an operating EBITDA margin of 18.02%, up 1,256 basis points, for the quarter ended September 30, 2026. Ind-Swift attributed the change to operating scale, improved product mix and export-led finished-dosage formulation sales.

What drove Ind-Swift’s Q2 FY27 revenue growth?

Ind-Swift’s Q2 FY27 operating revenue rose to Rs 234.89 crore for the quarter ended September 30, 2026, from Rs 156.43 crore in Q2 FY26 and Rs 186.09 crore in Q1 FY27. That represented growth of 50.15% year on year and 26.22% quarter on quarter, according to management’s standalone financial highlights.

The sequential rise added Rs 48.80 crore of operating revenue from Q1 FY27, while the year-on-year increase was Rs 78.46 crore. Management described Q2 FY27 as validation of its transition to a pure-play finished-dosage formulation platform, citing operating scale and a better product mix as the mechanisms behind revenue and profitability growth.

For H1 FY27, Ind-Swift reported operating revenue of Rs 420.97 crore, compared with Rs 310.02 crore in H1 FY26, a 35.79% increase. Q2 therefore accounted for Rs 234.89 crore of first-half revenue, compared with Rs 186.09 crore in Q1 FY27, showing that reported sales growth accelerated in the second quarter.

How did Ind-Swift’s profitability change in Q2 FY27?

Ind-Swift’s operating earnings before interest, tax, depreciation and amortisation, or EBITDA, increased to Rs 42.33 crore in Q2 FY27 from Rs 8.55 crore a year earlier and Rs 33.32 crore in Q1 FY27. Operating EBITDA was therefore 4.95 times the Q2 FY26 level and 27.04% above the preceding quarter.

Operating EBITDA margin reached 18.02% in Q2 FY27, expanding by 1,256 basis points year on year and 11 basis points quarter on quarter. Management linked the margin change partly to raw-material expenses declining to 45.15% of revenue from 49.38% in Q2 FY26, which it said reflected business-mix optimisation and operating leverage.

Profit after tax, or PAT, was Rs 31.03 crore in Q2 FY27, up 3.54 times year on year and 26.96% from Q1 FY27. PAT margin was 13.21%, an increase of 761 basis points from a year earlier. In H1 FY27, operating EBITDA was Rs 75.65 crore, up 4.45 times year on year, and the EBITDA margin was 17.97%, up 1,254 basis points.

Which businesses and products supported Ind-Swift’s sales?

Ind-Swift said exports represented 82.7% of Q2 FY27 sales and domestic operations 17.3%, making international business the larger reported sales channel. Management said its export footprint was the primary growth engine, while domestic verticals provided cash-flow stability; for H1 FY27, it said the mix was approximately 83% exports and 17% domestic revenue.

Own brands contributed 55.75% of quarterly sales and 69% of export sales, supported by direct marketing and field-force expansion in Gulf Cooperation Council countries, Central Asia and Africa. Contract manufacturing represented 26.99% of sales, while branded generics from the Healthcare and Agile divisions accounted for 6.84% and the Ethical division contributed 5.43%, led by chronic, paediatric and gynaecology therapies.

Management said Q2 export revenue was approximately Rs 190 crore, including about Rs 65 crore from contract development and manufacturing organisation, or CDMO, revenue, and Rs 125 crore from own-brand products. It expects the mix to move towards 35% contract manufacturing and 65% own products. The Atorvastatin plus Ezetimibe molecule generated about Rs 58 crore in Q2 FY27, up from about Rs 25 crore in Q1 FY27.

Ibuprofen was another cited contributor to the CDMO pipeline: management said it generated approximately Rs 15 crore to Rs 16 crore in H1 FY27 and estimated about Rs 20 crore in Q3 FY27 and Rs 20 crore to Rs 25 crore in Q4 FY27. Commercial supplies of Ibuprofen sachet and Macrogol sachet had begun, while the Clarithromycin product completed commercial validation and awaited approval of a customer-filed European variation before batches could start.

What does Ind-Swift expect for FY27 and beyond?

Ind-Swift reiterated management’s guidance for more than 50% revenue growth in FY27 after reporting Rs 420.97 crore of H1 FY27 operating revenue. The chief financial officer said on the November 4, 2026 call that management felt it was in a comfortable position to achieve the projected FY27 numbers, but did not provide a revised annual revenue figure.

On margins, management said its internal target was 22% and expected revenue growth could lift the next quarter’s margin to between 19% and 20%. The chief financial officer added that the blended margin for FY27 should be more than 19%. These are management targets and expectations rather than reported results; Q2 FY27 operating EBITDA margin was 18.02%.

The company said its Rs 250 crore growth capital-expenditure programme was on track, covering the Samba facility’s European Union good manufacturing practice, or EU-GMP, upgrade, a Derabassi warehouse, research and development infrastructure and capacity debottlenecking. The Rs 45 crore Samba upgrade is intended to meet EU-GMP and Pharmaceutical Inspection Co-operation Scheme standards and support regulated-market access for topical and oral formulations.

Management said it expected a Brazilian ANVISA visit at Samba in the last quarter and expected European Pharmaceutical Inspection Co-operation Scheme approval at some point in the following year. Samba capacity utilisation was stated at 70% to 75% while expansion proceeds. Ind-Swift also said it had more than 900 product registrations across 85 countries, backed by more than 2,100 filed dossiers, with more than 330 additional registrations expected in FY27.

Conclusion

Ind-Swift’s first-half performance combined Rs 420.97 crore of operating revenue with a 17.97% operating EBITDA margin, while its Q2 sales mix remained led by exports at 82.7%. Lower raw-material expenses as a share of revenue, at 45.15% versus 49.38% a year earlier, accompanied the shift towards own brands and CDMO activity.

The next indicators are management’s expected Rs 20 crore of Q3 FY27 Ibuprofen revenue and Rs 20 crore to Rs 25 crore in Q4 FY27, as well as its target of more than 19% blended margin for FY27. Progress on the European variation for the Clarithromycin product, the expected ANVISA visit and the Rs 250 crore capital-expenditure programme will also determine the pace of planned expansion.